Kos Biotechnology Partners has successfully closed its inaugural global life sciences fund, amassing $123 million in capital commitments, marking a significant milestone in Greece's venture capital landscape.
The firm, which connects the US biopharma ecosystem with Europe, has garnered support from notable institutional investors, including the Hellenic Development Bank of Investments. This fund represents a historic launch as the first dedicated life sciences investment fund in Greece and stands out as one of the largest first-time life sciences VC launches in Europe.
Kos focuses on strategic investments across various stages of company development, targeting high-impact opportunities in biotech, pharma services, and tech-enabled technologies. The founders, Dr. Simos Simeonidis and Alex Tzoukas, leverage their extensive backgrounds in biomedical science and finance to enhance the life sciences ecosystem in Greece. Their expertise is complemented by an advisory network of industry leaders, which aids portfolio companies in scaling internationally.
With a clear investment strategy, Kos aims to support innovative solutions addressing unmet medical needs and accelerate drug discovery through advanced platforms. The firm has already initiated its investment activities, including a recent financing round for a tech-enabled pharma services provider and plans for further investments in the near future. This momentum highlights the potential of combining US innovation with European scientific advancements.